A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy

Novartis

Status and phase: Active, not recruiting; Phase 2

Conditions: Achilles Tendinopathy

Treatments: Drug: Placebo; Drug: NGI226

Study type: Interventional

Funder types: Industry

Identifiers

NCT05592990

2022-500863-10-00 (Other Identifier)

CNGI226A12201

Details and patient eligibility

About

The purpose of this study is to measure local and systemic safety and tolerability as well as improvement of Achilles tendon mechanical properties after a single peritendon injection of NGI226 MP in comparison to placebo MP in patients with mid-portion Achilles tendinopathy.

Enrollment: 45 patients

Sex: All

Ages: 30 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent must be obtained prior to all study specific screening procedures, as close to the start of the screening period as possible.
• Presence of clinically (local Achilles tendon pain on tendon-loading activities, pain on palpation at the level 2-6 cm proximal to the calcaneal insertion) and ultrasound (local tendon thickening with hypoechogenicities and irregular fibre orientation) or MRI diagnosed mid-portion Achilles tendinopathy with symptoms present ≥8 weeks but <12 months at screening.
• The Achilles tendinopathy must have been refractory to at least 6 weeks of conservative treatment (physiotherapy, NSAIDS, RICE), but participants do not need to be in physiotherapy at the time of study entry.

Exclusion criteria

• Medical condition that would affect safety of peritendon injection (e.g., peripheral vascular disease, use of anticoagulant medication)
• History of recurrent, acute, symptomatic infections, including outbreaks of oral or genital herpes (> 2 symptomatic infections or >2 courses of anti-infective treatments required in the last 6 months; active systemic infection during last 2 weeks; known active infections (e.g. chronic or active Hepatis B or C, HIV) - simple cold excluded
• History or evidence of clinically significant cardiac or cardiovascular disease
• History of deep vein thrombosis, pulmonary embolism or evidence of primary or secondary hypercoagulable states
• History of surgical intervention for the treatment of tendinopathy, history of ankle surgery, ankle arthritis, traumatic, inflammation or deformity of ankle
• History of full-thickness tear or complete rupture of the Achilles tendon

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

45 participants in 2 patient groups, including a placebo group

NGI226

Experimental group

Description:

single peritendon injection

Treatment:

Drug: NGI226

Placebo

Placebo Comparator group

Description:

single peritendon injection

Treatment:

Drug: Placebo